Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Abemaciclib in Indian Women With Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE4
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE2
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL
- Status
- COMPLETED
- Phase
- PHASE2
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
- Status
- RECRUITING
- Phase
- PHASE2
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy
- Status
- COMPLETED
- Phase
- N/A
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients
- Status
- COMPLETED
- Phase
- PHASE2
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2